Article ID Journal Published Year Pages File Type
6189968 Bulletin du Cancer 2016 11 Pages PDF
Abstract
Ibrutinib is a new-targeted therapy that irreversibly and specifically inhibits the Bruton's Tyrosine Kinase (BTK), a key component of the signaling pathways of B cells. The results are very encouraging as monotherapy in the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia. Following the results of recent studies, ibrutinib is now available in France for these three diseases.
Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , , , , ,